104 results on '"Lopez-Talavera, Juan Carlos"'
Search Results
2. Corrigendum to: “Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results” [JHEP Reports 5 (2019) 101041]
3. Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results
4. IMPROVEMENTS IN INSULIN SENSITIVITY SEEN IN PATIENTS WITH TYPE 2 DIABETES AFTER REVITA® DMR IS ASSOCIATED WITH A DECREASE IN GLUCAGON, GLUCOSE, AND GIP AFTER A MIXED MEAL TOLERANCE TEST
5. Islet Growth Factors
6. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
7. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia
8. A Gut-Centric Model of Metabolic Homeostasis
9. Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables
10. Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
11. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: The randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
12. Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection
13. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
14. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B
15. Peginterferon Lambda-1a (Lambda) compared to peginterferon alfa-2a (alfa) in treatment-naïve patients with HCV genotypes (G) 2 or 3: first SVR24 results from emerge phase IIb
16. Pegylated Interferons Lambda-1a and Alfa-2a Display Different Gene Induction and Cytokine Release Profiles in Both Human Hepatocytes and Peripheral Blood Mononuclear Cells: 1885
17. Baseline CXCR3 Ligand Levels are Associated With Early Virologic Response to Treatment With Peginterferon Lambda-1a in Chronic Hepatitis C Patients in a Phase 2b Study: 1870
18. Peginterferon Lambda-1a (Lambda) is less likely to induce clinically significant neuropsychiatric symptoms during the treatment of chronic hepatitis C virus (HCV) infection, compared to peginterferon alfa-2a (Alfa): 793
19. Peginterferon Lambda-1a (Lambda) is Associated With Less Autoimmune Thyroid Disease and Serious Autoimmune Disease Than Peginterferon Alfa-2a (Alfa) When Used in Combination With Ribavirin (RBV) for the Treat ment of Chronic Hepatitis C Virus Infection: 781
20. Peginterferon Lambda-1a (Lambda) Compared to Peginterferon Alfa-2a (Alfa) in Treatment-Naïve Patients With HCV Genotypes (GT) 1 or 4: SVR24 Results From EMERGE Phase 2b: 214
21. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
22. 121-LB: Durable Glycemic Improvements after Duodenal Mucosal Resurfacing (DMR) in Patients with Type 2 Diabetes (T2D): 48-Week Results from the REVITA-2 European Cohort
23. OR30-07 Mixed Meal Tolerance Test (MMTT) Results from Revita-2, the First Randomized, Sham-Controlled, Double-Blind, Prospective, Multicenter Study of Duodenal Mucosal Resurfacing (DMR) Safety and Efficacy in Patients with Sub-Optimally Controlled Type 2 Diabetes (T2D)
24. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
25. Morpholino oligonucleotide-triggered β-catenin knockdown compromises normal liver regeneration
26. Proximal and Distal Gut Mucosa Adapt Differently to Westernized Diet, Promoting an Insulin-Resistant Dysmetabolic State
27. Hepatocyte Growth Factor Gene Therapy for Pancreatic Islets in Diabetes: Reducing the Minimal Islet Transplant Mass Required in a Glucocorticoid-Free Rat Model of Allogeneic Portal Vein Islet Transplantation
28. Using β-Cell Growth Factors to Enhance Human Pancreatic Islet Transplantation*
29. Transgenic overexpression of hepatocyte growth factor in the β-cell markedly improves islet function and islet transplant outcomes in mice
30. Tyrosine Kinase Inhibition Ameliorates the Hyperdynamic State and Decreases Nitric Oxide Production in Cirrhotic Rats with Portal Hypertension and Ascites
31. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus
32. Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials
33. 1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis
34. Islet Growth Factors
35. Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 2: Exposure–response analyses for efficacy and safety variables
36. Derivation of Phase 3 dosing for peginterferon lambda‐1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates
37. Distribution and clinical correlates of viral and host genotypes in C hinese patients with chronic hepatitis C virus infection
38. Hepatocytes Undergo Phenotypic Transformation to Biliary Epithelium in Organoid Cultures
39. Pharmacokinetics and Pharmacodynamics of Pegylated Interferon Lambda-1 in Cynomolgus Monkeys
40. Single- and Multiple-Ascending-Dose Studies of the NS3 Protease Inhibitor Asunaprevir in Subjects with or without Chronic Hepatitis C
41. Parathyroid Hormone–Related Protein as a Regulator of pRb and the Cell Cycle in Arterial Smooth Muscle
42. Adenovirus-mediated Hepatocyte Growth Factor Expression in Mouse Islets Improves Pancreatic Islet Transplant Performance and Reduces Beta Cell Death
43. Hepatocytes undergo phenotypic transformation to biliary epithelium in organoid cultures
44. Interleukin-6, Nitric Oxide, and the Clinical and Hemodynamic Alterations of Patients With Liver Cirrhosis
45. Tumor necrosis factor α: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats
46. Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis
47. Drug Therapy for Acute Bleeding From Portal Hypertensive Gastropathy
48. Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
49. Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled trials.
50. The processing and utilization of hepatocyte growth factor/scatter factor following partial hepatectomy in the rat.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.